{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"CCS1477"},{"type":"CodeName","name":"CCS-1477"},{"type":"CodeName","name":"CCS 1477"},{"type":"Synonym","name":"p300 HAT/CREB binding protein inhibitor CCS1477"}],"definition":{"html":"An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, p300/CBP bromodomain inhibitor CCS1477 selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.","text":"An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, p300/CBP bromodomain inhibitor CCS1477 selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C160195","nciConceptName":"Inobrodib","termId":797847,"name":"p300/CBP bromodomain inhibitor CCS1477","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"inobrodib"}],"links":null}